Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Prelude Therapeutics Incorporated (PRLD) had Return on Tangible Equity of -31.10% for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-32.09M |
|
-- |
|
-- |
|
$34.61M |
|
$-34.61M |
|
$2.52M |
|
$-32.09M |
|
$-32.09M |
|
$-32.09M |
|
$-32.09M |
|
$-32.09M |
|
$-32.09M |
|
$-34.61M |
|
$-34.09M |
|
75.99M |
|
75.99M |
|
$-0.42 |
|
$-0.42 |
|
| Balance Sheet Financials | |
$102.40M |
|
$6.39M |
|
$38.86M |
|
$141.26M |
|
$19.79M |
|
-- |
|
$18.30M |
|
$38.08M |
|
$103.18M |
|
$103.18M |
|
$103.18M |
|
56.45M |
|
| Cash Flow Statement Financials | |
$-34.23M |
|
$62.19M |
|
$-0.16M |
|
$16.52M |
|
$44.31M |
|
$27.80M |
|
$3.83M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.18 |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-34.28M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-31.10% |
|
|
Return on Tangible Equity |
-31.10% |
-22.71% |
|
-31.10% |
|
$1.83 |
|
$-0.45 |
|
$-0.45 |
|